Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?

About 35% of patients affected by erectile dysfunction (ED) do not respond to oral phosphodiesterase-5 inhibitors (PDE5i) and more severe vasculogenic refractory ED affects diabetic patients. Innovative approaches, such as regenerative therapies, including stem cell therapy (SCT) and platelet-rich p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonanni, Michela, Rehak, Laura, Massaro, Gianluca, Benedetto, Daniela, Matteucci, Andrea, Russo, Giulio, Esperto, Francesco, Federici, Massimo, Mauriello, Alessandro, Sangiorgi, Giuseppe Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138496/
https://www.ncbi.nlm.nih.gov/pubmed/35625828
http://dx.doi.org/10.3390/biomedicines10051091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138496/
https://www.ncbi.nlm.nih.gov/pubmed/35625828
http://dx.doi.org/10.3390/biomedicines10051091

Ejemplares similares